Clinical trials involving type I and III interferons in COVID-19
| Interferon | Phase 1 | Phase 2 | Phase 3 | Phase 4 |
|---|---|---|---|---|
| Interferon alpha | – | NCT04379518 NCT04480138 | NCT04349410 NCT04320238 NCT04534725 | NCT04254874 |
| Interferon beta | NCT04293887 | NCT04449380 NCT04343768 NCT04469491 NCT04276688 NCT04521400 NCT04385095 NCT04465695 NCT04350281 NCT04494399 | NCT04324463 NCT04315948 NCT04492475 NCT04552379 | NCT04350671 NCT04350684 NCT02735707 |
| Interferon lambda | – | NCT04343976 NCT04388709 NCT04534673 NCT04354259 NCT04344600 | – | – |
Data from Clinicaltrials.gov as of November 2, 2020.